Among the most exciting developments are blood tests that detect AD-related proteins, offering a non-invasive, accessible alternative to CSF or imaging. Tests measuring p-tau217, amyloid-beta ratios, or neurofilament light chain can identify brain changes with up to 90% accuracy,